Polymer-drug Conjugates Market Increase In
Transactional And Analytical Needs Across
Several Industries 2026
Polymer-drug conjugates are nano-sized drug products currently used for treating cancer and
hepatitis. Polymers are now being synthesized to be sensitive to specific enzymes that are
apparent in diseased tissue. Conventional polymers are used in polymer-drug conjugates such as
cellulose and chitin can be degraded through enzymatic activity and acidity. The drugs remain
attached to the polymer and are not activated until the enzymes associated with the diseased
tissue are present. This process significantly minimizes damage to healthy tissues.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/2260
Polymer-drug Conjugates Market Driver
New pipeline drugs developed using polymer-drug conjugation are expected to propel growth of
the polymer-drug conjugates market. For instance, in march 2016, National Cancer Institute
(NCI) started undergoing phase II clinical study for CRLX101, a nanoparticle drug conjugate
composed of 20(S)-Camptothecin conjugated to a linear, cyclodextrin-polyethylene glycol-based
polymer, for the treatment of metastatic prostate cancer and the trial is expected to complete
by March 2020.
Polymer-drug Conjugates Market Restraint
Limited use of polymer-drug conjugates is expected to restrain growth of the polymer-drug
conjugates market. For instance, according to an article published in Bioengineering and
Translational Medicine 2016, polymer-drug conjugates are formed by covalent linkage between
the drug and polymer and not all of the drugs have chemical functional groups for covalent
conjugation. Moreover, they offer triggered drug release only at the tumor tissue or cell.
Lack of standard and optimized preclinical or clinical protocols to evaluate polymer-drug
conjugate stability, tumor penetration, metabolism, and toxicity are hindering growth of the
polymer-drug conjugates market.